Mitoxantrone 2HCl

Catalog No.S2485 Synonyms: NSC-301739

Mitoxantrone 2HCl Chemical Structure

Molecular Weight(MW): 517.4

Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

5 Customer Reviews

  • Immunohistochemistry and quantification of cleaved caspase 3 expression in DU145-DR tumor xenografts from (D). Scale bar, 100 mm. Data represent the mean ± SD. *p < 0.05.

    Cell, 2018, 174(5):1200-1215. Mitoxantrone 2HCl purchased from Selleck.

  • Blockade of USP11 by pharmacological inhibitor Mitoxantrone destabilizes XIAP protein in MDA-MB-231 cells. MDA-MB-231 cells were treated with Mitoxantrone at indicated concentration for 24 h.

    EBioMedicine, 2017, 15:48-61. Mitoxantrone 2HCl purchased from Selleck.

  • C18SH: C18NH2 mixed monolayer. Panel A: Cyclic voltammograms of MTX at various scan rates (1) 9 mV/s, (2) 36 mV/s, (3) 64 mV/s, (4) 100 mV/s. Panel B: Bode plots (circles) with fit (solid line) and corresponding electrical equivalent circuit (inset); 1×10-5 M MTX(Mitoxantrone) in aqueous 0.1 M LiClO4, pH = 5.6, E = 0.4 V.

    Electrochimica Acta, 2015, 165:430-442.. Mitoxantrone 2HCl purchased from Selleck.

  • Rate of apoptosis induced by 24-h treatment of 1 µM mitoxantrone normalized to DMSO-treated samples in sporadic gastric cancer SNU-16 and hereditary c.1380delA SB.mhdgc-1 cells. Flow cytometry profiles of FITC-labeled anti-BrdU staining of 3′-hydroxyl (OH) termini of double- and single-stranded DNA, relative BrdU fractions normalized to DMSO-treated control shown on the right.

    J Transl Med, 2017, 15(1):92. Mitoxantrone 2HCl purchased from Selleck.

  • The viability of LKB1 knockdown cells was decreased more significantly compared with control cells after treatment with mitoxantrone. *P<0.01, vs LKB1-KD; **P<0.001, vs LKB1-KD.

    Mol Cell Biochem, 2017, 434(1-2):25-32. Mitoxantrone 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively.
Targets
Topoisomerase II [1]
In vitro

Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), a marker of the activation of caspases, in all the patients studied, demonstrating that the cytotoxic effect of mitoxantrone is due to induction of apoptosis. [1] Mitoxantrone activates NFkappaB and stimulates IkappaBalpha degradation in the promyelocytic leukemia cell line HL60 but not in the variant cells, HL60/MX2 cells, which lack the beta isoform of topoisomerase II and express a truncated alpha isoform that results in an altered subcellular distribution. [2] Mitoxantrone inhibits proliferation of activated PBMCs, B lymphocytes, or antigen-specific T-cell lines (TCLs) stimulated on antigen-presenting cells (APCs) in a dose-dependent manner. Mitoxantrone induces apoptosis of PBMCs, monocytes and DCs at low concentrations, whereas higher doses causes cell lysis. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 cell MXTDfZRwfG:6aXPpeJkh[XO|YYm= MV60PEBp Ml3sR5l1d3SxeHnjJJBwfGWwY4mgdoVyfWm{ZXSgeI8hcW6qaXLpeEBNOTJzMDDj[YxtKGe{b4f0bEBjgSB3MDWgZYZ1\XJiY3XscEBlenWpIHPvcpRi[3RiZn;yJFQ5KGi{czygTWM2OD12ZT2wOUDPxE1? MUK5N|cyOjRy
HL60 cells MoLPR5l1d3SxeHnjbZR6KGG|c3H5 NU\q[WhNPDhiaB?= MnjwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUCuN|Mh|ryP NIK2c4oyPzl4MkCyPC=>
MDA435/LCC6 cells NFHzWINRem:uaX\ldoF1cW:wIHHzd4F6 M1\1PWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgUWRCPDN3L1zDR|Yh[2WubIOgZpkhTUyLU1GsJGlEPTB;MD6zOUBvVQ>? M4LCRVE4OTV2NUC1
A2780-cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;3VIREd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgRVI4QDBvY3XscEBoem:5dHigZpkhPTBnLDDJR|UxRTBwNUWgcm0> MV25O|A{PDdz
G-361 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;neWN6fG:2b4jpZ{Bxd3SnbnP5JJJmeXWrcnXkJJRwKGmwaHnibZQhTy1|NkGgZ4VtdCCpcn;3eIgh[nliNUClMEBKSzVyPUCuOlUhdk1? MWS5N|cyOjRy
human HL60 cells M1TYWnBzd2yrZnXyZZRqd25iYYPzZZk> NHvzU4w4OiCq M2HYfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTJwNTDuUS=> MYeyNlk1PDF{MR?=
human K562 cells NG\XXmVEgXSxdH;4bYNqfHliYYPzZZk> M1u4U|Uh\GG7cx?= M3TWSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgOUBl[Xm|IHL5JHhVXCCjc4PhfUwhUUN3ME2yMlYhdk1? NFPqfYQyQDB5NkG0NC=>
CH1 cell M4rieGN6fG:2b4jpZ4l1gSCjc4PhfS=> NWHKU4xMS3m2b4TvfIlkKHCxdHXuZ5khemWzdXny[YQhfG9iaX7obYJqfCCFSEGgZ4VtdCCpcn;3eIgh[nliNUClMEBKSzVyPUKuOlUhdk1? MkWxPVM4OTJ2MB?=
MES-SA cells MUTQdo9tcW[ncnH0bY9vKGG|c3H5 Mny0O|IhcA>? NXG2fnNtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOTVNvU1GgZ4VtdHNiYomgUXRVKGG|c3H5JIFnfGW{IEeyJIhzeyxiSVO1NF0{KG6P NIXudXoyPjh{NEe1NS=>
A549 cells MlvmSpVv[3Srb36gZZN{[Xl? MVvBZ5Rqfmm2eTDh[4FqdnO2IFG1OFkh[2GwY3XyJINmdGxibHnu[UwhUUN3ME2zMlEhdk1? MoXpPFk3ODV3OB?=
LoVo cells Ml:wR5l1d3SxeHnjbZR6KGG|c3H5 M1y3VVE1PCCq MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOjbnPldkBk\WyuIHzpcoUhf2G|IHTleIVzdWmwZXSgZYZ1\XJiMUS0JIhzNCCLQ{WwQVMvOyCwTR?= MYixOVQ2PjJ4OB?=
P388 cells NGLifJJRem:uaX\ldoF1cW:wIHHzd4F6 Ml\QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDQN|g5KGOnbHzzJIJ6KEWOSWPBMEBKSzVyPUSuN{BvVQ>? NIKzOW0yPzF3NEWwOS=>
human Daudi cells MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 MmTsO|IhcA>? Mm\yRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGYYXkbUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTVibl2= NF\qUFIzPTl7OEWwOC=>
SKOV-3 cell M33TT2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYfDfZRwfG:6aXOgdI91\W6leTDy[ZF2cXKnZDD0c{BqdmirYnn0JHNMV1ZvMzDj[YxtKGe{b4f0bEA2OCVuIFnDOVA:PS5|IH7N NGPFO206OzdzMkSw
OVCAR-3 cell NYG5XmFCTnWwY4Tpc44h[XO|YYm= M4XBTmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iT2\DRXIuOyClZXzsJIxqdmW|LDDJR|UxRTVwODDuUS=> MkfVPFk3ODV3OB?=
human MES-SA cells NEPTXGVRem:uaX\ldoF1cW:wIHHzd4F6 NWDZXXB{PzJiaB?= NF7JclNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3FV{1USSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[gcm0> MlzNNlU6QTh3MES=
PC3 cancer cell MXjDfZRwfG:6aXPpeJkh[XO|YYm= NXLvfFVOOTR2IHi= NX7M[XlOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPhcoNmeiClZXzsJIxqdmVid3HzJIRmfGW{bXnu[YQh[W[2ZYKgNVQ1KGi{LDDJR|UxRTdibl2= MlK0NVU1PTZ{Nki=
MXF7 breast cell NI\TUnRHfW6ldHnvckBie3OjeR?= MX3BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCvYX3tZZJ6KGOjcnPpco9u[SC|ZX7zbZRqfmViTWjGO{BjemWjc4SgZ4VtdCCuaX7lMEBKSzVyPUiuO{BvVQ>? M1TDXFg6PjB3NUi=
HT-29 cell MlfsR5l1d3SxeHnjbZR6KGG|c3H5 NXfOWlhjOTR2IHi= NXLacXBKS3m2b4TvfIlkKHCxdHXuZ5khemWzdXny[YQhfG9iaX7obYJqfCCKVD2yPUBk\WyuIHfyc5d1cCCkeTC1NEUh[W[2ZYKgZ4VtdCCmcoXnJINwdnSjY4Sg[o9zKDF2NDDodpMtKEmFNU2wMlAyKM7:TR?= M3XNdlk{PzF{NEC=
HEK293 cells M2nWPWN6fG:2b4jpZ4l1gSCjc4PhfS=> NHPrWVI4OiCq MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjBzIN88US=> NWLn[W1JOjR4MUG4PVM>
MKN45 cells MVXDfZRwfG:6aXPpeJkh[XO|YYm= MlLtNVQ1KGh? MmrJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWtPPDViY3HuZ4VzKGOnbHygcIlv\SC5YYOg[IV1\XKvaX7l[EBi\nSncjCxOFQhcHJuIFnDOVA:OC5yMUKg{txO Ml\vNVU1PTZ{Nki=
MES-SA cells NUKyfpRoS3m2b4TvfIlkcXS7IHHzd4F6 MnHVO|IhcA>? MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAyOiEQvF2= M4Pjc|IyPDR2MkC1
FM3 cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 NELybGQ4OiCq NX7tOnFvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGUVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCxN{DPxE1? NUTzOVlHOjV7OUi1NFQ>
MCF-7 cells NYrxe2tuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFXBNYNKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhcHWvYX6geJVud3JiY3XscEBtcW6nIF3DSk04KGK{ZXHzeEBi\GWwb3PhdoNqdm:vYTygTWM2OD1yLkCyJO69VQ>? MoD1O|g2OzN2NR?=
human small-cell lung cancer MYfDfZRwfG:6aXPpeJkh[XO|YYm= NEG0dYZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB{dWGubD3j[YxtKGy3bnegZ4Fv[2W{IDjTR2xEMSxiSVO1NF0xNjB{IN88US=> MVq4NlU5QDN3
human HCT116 cells M4LBO2N6fG:2b4jpZ4l1gSCjc4PhfS=> MUS3NkBp NUXvbpg{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMkKg{txO M4HLNVIyPDR2MkC1
human HCT116 cells NILWd5pRem:uaX\ldoF1cW:wIHHzd4F6 MYW3NkBp MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMEK1JO69VQ>? Mn\6NlU6QTh3MES=
NCI-H460 cells NYTUOIpQS3m2b4TvfIlkcXS7IHHzd4F6 M2LOflQ5KGh? NFvqV25EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDh[pRmeiB2ODDodpMh[nlicnXzZZp2emmwIHT5[UBie3OjeTygSWM2OD1yLkCzJO69VQ>? MXOyN|k5QDN3MR?=
CCRF-CEM cells NWHVc5hHS3m2b4TvfIlkcXS7IHHzd4F6 MYm0PEBp NGDXfFREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliY3XscJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;MD6wN|Yh|ryP Mn3WNlI2QDJ7OUG=
HeLa cells MnTlVJJwdGmoZYLheIlwdiCjc4PhfS=> NGLXXZg4OiCq NXTa[IFiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wOFQh|ryP NEHLOGgzPTl7OEWwOC=>
NCI60 cells NFP0bZRHfW6ldHnvckBie3OjeR?= MWi0PEBp MWHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1m2NEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTR5Lki2JI5O MVmxPFcyPTd6Nh?=
UACC375 cell MVXGeY5kfGmxbjDhd5NigQ>? MULBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCvZXzhco9u[SCXQVPDN|c2KGOnbHygcIlv\SxiSVO1NF0xNjB2ODFOwG0> NWjPZo1SQDl4MEW1PC=>
HT1080 cell NUCyZ3p3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5idIXtc5Ih[2WubDDsbY5mKEiWMUC4NEwhUUN3ME2wMlA3PiEQvF2= M1HuXVc5PTN|NEW=
MES-SA/Dx5 cells MnW4VJJwdGmoZYLheIlwdiCjc4PhfS=> M2Xtc|czKGh? NV[zZm0{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yN{Og{txO NYnUfWVFOjV7OUi1NFQ>
SF268 cells NHLh[oxRem:uaX\ldoF1cW:wIHHzd4F6 NV:2NopkPDhiaB?= NFL3clBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPGNlY5KGOnbHzzJIFnfGW{IES4JIhzeyxiRVO1NF0xNjN{IN88US=> M3;BOVI{Ozl3NkW2
KB/HeLa cells MUDQdo9tcW[ncnH0bY9vKGG|c3H5 M2jufFQ5KGh? M3X4bGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KvTIVN[SClZXzsd{Bi\nSncjC0PEBpenNuIFXDOVA:OC5|NjFOwG0> NHXxOFQzOzN7NU[1Oi=>
K562 cells MoDNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHGzcYM4OiCq NYXKPW1OT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSVIH3leIhw\CxiSVO1NF0xNjR{IN88US=> NVHKTWRXOTh{NUi0OFI>
MDA-MB-231 cells M17lWXBzd2yrZnXyZZRqd25iYYPzZZk> M4i3[VczKGh? M3PLO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCkeTDXV3QuOSCvZYToc4Qh[W[2ZYKgO|IhcHK|LDDJR|UxRTBwOU[g{txO MX[xO|M{PTF6OR?=
SF268 cells MkXpR5l1d3SxeHnjbZR6KGG|c3H5 M3LK[|Q5KGh? NWfZ[YtHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjl5IN88US=> MVixO|k3OjB{OB?=
HCT116 cells MXrDfZRwfG:6aXPpeJkh[XO|YYm= MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTNwOU[g{txO MV6yNFk2OTV6Mh?=
U937 cells MlTGR5l1d3SxeHnjbZR6KGG|c3H5 NEn0fpJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD14LkKg{txO NHnrPW8yQTZzNUmwNC=>
HepG2 cells MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 NWXHWng1PDhiaB?= M1TuSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zMT6wOUDPxE1? M3HWWVI1Pzl2N{S3

... Click to View More Cell Line Experimental Data

In vivo Mitoxantrone transiently decreases the growth rate of HID xenografts in mice but does not affect that of PAC120 xenografts. [4] Mitoxantrone results in the severity of the cardiac lesions and the nephropathy and the intestinal toxicity in spontaneously hypertensive rats. Mitoxantrone and iron(III) form a strong 2:1 complex, in which mitoxantrone may be acting as a tridentate ligand. [5]

Protocol

Solubility (25°C)

In vitro DMSO 89 mg/mL (172.01 mM)
Water 89 mg/mL (172.01 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 517.4
Formula

C22H29ClN4O6.2HCl

CAS No. 70476-82-3
Storage powder
in solvent
Synonyms NSC-301739

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03860844 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia Sanofi March 11 2019 Phase 2
NCT03860844 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia Sanofi March 11 2019 Phase 2
NCT03839446 Recruiting Acute Myeloid Leukemia Michael Boyiadzis|University of Pittsburgh February 28 2019 Phase 2
NCT03839446 Recruiting Acute Myeloid Leukemia Michael Boyiadzis|University of Pittsburgh February 28 2019 Phase 2
NCT03735446 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes Dana-Farber Cancer Institute|Eli Lilly and Company January 18 2019 Phase 1
NCT03735446 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes Dana-Farber Cancer Institute|Eli Lilly and Company January 18 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Mitoxantrone 2HCl | Mitoxantrone 2HCl supplier | purchase Mitoxantrone 2HCl | Mitoxantrone 2HCl cost | Mitoxantrone 2HCl manufacturer | order Mitoxantrone 2HCl | Mitoxantrone 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID